PDF is available of LRG Science here.
Additional Commentary: It’s Time to Rethink Placebos in Advanced GIST
This Breaking News issue showcases additional commentary on our September 2021 issue which, based on current studies, asserts the belief that placebos do not benefit patients with advanced disease. The article entitled “It’s Time to Rethink Placebos in Advanced GIST”, illustrates the effect of placebos in trials and appeals to stakeholders to begin discussing alternatives and changes in order to save lives by extending the time on treatment instead of using placebos in advanced trials. After all the evidence is considered, the question “Do placebos in clinical trials benefit patients with advanced GIST?” is answered and the author encourages discussion between primary stakeholders as the next step for this issue.
The commentary below was provided by a team of GIST experts from Instituto Alexander Fleming in Buenos Aires, Argentina. The original article is available at https://indd.adobe.com/view/60d0a521-a763-4c5b-a011-ffc5318336ab. We invite any commentary on our LRG Science articles.
We welcome commentary on this article and invite new submissions for 2021 and 2022. To inquire further or to submit commentary, please email Mary Garland, Director of Communications: email@example.com